AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2015

Jul 17, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2015-07-16

Reporting Person: Higgons John Duncan (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-07-16	Common stock	M	8264	$0.3025	Acquired	130099	Direct
2015-07-16	Common stock	M	11736	$0.3025	Acquired	141835	Direct
2015-07-16	Common stock	S	20000	$114.02	Disposed	121835	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-07-16	Stock option (right to buy)	$0.3025	M	8264	Disposed	2019-08-12	Common stock (8264)	Direct
2015-07-16	Stock option (right to buy)	$0.3025	M	11736	Disposed	2019-08-12	Common stock (11736)	Direct

Footnotes

F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $113.02 to $115.20. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: This option was granted on August 13, 2009. The shares underlying this option vest as to 25% of the shares on May 18, 2010, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F5: This option was granted on August 13, 2009. The shares underlying this option vest as to 25% of the shares on June 13, 2010, with the remaining 75% vesting in 36 equal monthly installments thereafter.